http://dx.doi.org/10.1007/s00216-010-4192-8
pubmed: 20865407
scopus: 78650176365
A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
December 2010
Article
| Related Files |
|---|
View PDF Version
(fulltext.pdf, 0.2MB) |
An analytical assay has been developed and validated for ultrafast and high-throughput mass spectrometric determination of pemetrexed concentrations in plasma using matrix assisted laser desorption/ionization-triple quadrupole-tandem mass spectrometry. Patient plasma samples spiked with the internal standard methotrexate were measured by multiple reaction monitoring. The detection limit was 0.4 fmol/μL, lower limit of quantification was 0.9 fmol/μL, and upper limit of quantification was 60 fmol/μL, respectively. Overall observed pemetrexed concentrations in patient samples ranged between 8.7 (1.4) and 142.7 (20.3)∈pmol/μL (SD). The newly developed mass spectrometric assay is applicable for (routine) therapeutic drug monitoring of pemetrexed concentrations in plasma from non-small cell lung cancer patients.
- plasma
- concentration
- sample
- patient
- pemetrexed
- recovery
- assay
- analysis
- drug monitoring
- cancer
- level
- spectrometry
- pemetrexed concentrations
- maldi-qqq-m
- accuracy
- precision
- 20 μ l
- 1.5 μ l
- validation
- osterhaus ad
